Abstract | Background: Materials and methods: Nine patients received GM-CSF therapy who displayed moderate neutropenia with absolute neutrophil counts (ANC) < 1,500 cells/mm3 with concomitant declination of circulating CAR T-cell. Results: The median duration of GM-CSF intervention was 15 days (4-30). CAR T-cell expansion was observed in peripheral blood (PB) of seven patients (7/9). The median baseline and peak CAR T cells count in PB of the seven patients with CAR T-cell expansion were 0.85 × 106/L (0-50.9) and 6.06 × 106/L (1.43-112.55). And the peaks of CAR T-cell levels in PB appeared in day 7 (2-11) following the initiation of GM-CSF administration with increases of 2.84 × 106/L (0.38-61.65). Also, increased white blood cells in PB were observed in all patients. The median onset and duration time of WBC recovery were 9 (1-14) and 17 (3-53) days. Moreover, the increment of WBC, neutrophil, lymphocyte and CD3-CD16 + CD56 + natural killer cell in PB was observed. In addition, no CRS or fatal infection occurred during GM-CSF treatment. Conclusion: This study provides evidence for the clinical feasibility of combining CAR T-cell therapy with the GM-CSF to treat neutropenia patients with concomitant declination of circulating CAR T-cell.
|
Authors | Ying Jiang, Dan Feng, Chun Wang, Yanlei Zhang, Chuxian Zhao, Su Li, Youwen Qin, Alex H Chang, Jun Zhu |
Journal | Frontiers in medicine
(Front Med (Lausanne))
Vol. 9
Pg. 1042501
( 2022)
ISSN: 2296-858X [Print] Switzerland |
PMID | 36405594
(Publication Type: Journal Article)
|
Copyright | Copyright © 2022 Jiang, Feng, Wang, Zhang, Zhao, Li, Qin, Chang and Zhu. |